In 2022, the European LeukemiaNet (ELN) risk classification system for acute myeloid leukemia patients modified risk genes including CEBPA mutation status, myelodysplasia‐related gene mutations and internal tandem duplications of FLT3 (FLT3‐ITD). This evidence concerns the gene FLT3 and acute myeloid leukemia.